Pharmacokinetics of anti-IL17A and anti-IL22 peptide–antibody bispecific genetic fusions in mice
- 1 February 2014
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 18 (2) , 225-227
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptidesmAbs, 2013
- Pyroglutamate and O-Linked Glycan Determine Functional Production of Anti-IL17A and Anti-IL22 Peptide-Antibody Bispecific Genetic FusionsJournal of Biological Chemistry, 2013
- Pharmacokinetics of recombinant bifunctional fusion proteinsExpert Opinion on Drug Metabolism & Toxicology, 2012
- Dual targeting strategies with bispecific antibodiesmAbs, 2012
- Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/-micemAbs, 2010
- Interleukin-17 and Type 17 Helper T CellsNew England Journal of Medicine, 2009
- Bispecific Antibodies for Cancer TherapyImmunotherapy, 2009
- Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune diseaseInternational Immunology, 2006
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesJournal of Experimental Medicine, 2006
- New protein engineering approaches to multivalent and bispecific antibody fragmentsImmunotechnology, 1997